GB2246783B - Fusion proteins containing n-terminal fragments of human serum albumin - Google Patents

Fusion proteins containing n-terminal fragments of human serum albumin

Info

Publication number
GB2246783B
GB2246783B GB9119043A GB9119043A GB2246783B GB 2246783 B GB2246783 B GB 2246783B GB 9119043 A GB9119043 A GB 9119043A GB 9119043 A GB9119043 A GB 9119043A GB 2246783 B GB2246783 B GB 2246783B
Authority
GB
United Kingdom
Prior art keywords
fusion proteins
serum albumin
human serum
proteins containing
terminal fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
GB9119043A
Other versions
GB2246783A (en
GB9119043D0 (en
Inventor
David James Ballance
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albumedix Ltd
Original Assignee
Delta Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd
Publication of GB9119043D0 publication Critical patent/GB9119043D0/en
Publication of GB2246783A publication Critical patent/GB2246783A/en
Application granted granted Critical
Publication of GB2246783B publication Critical patent/GB2246783B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
GB9119043A 1989-04-29 1991-09-06 Fusion proteins containing n-terminal fragments of human serum albumin Expired - Lifetime GB2246783B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898909916A GB8909916D0 (en) 1989-04-29 1989-04-29 Polypeptides

Publications (3)

Publication Number Publication Date
GB9119043D0 GB9119043D0 (en) 1991-12-04
GB2246783A GB2246783A (en) 1992-02-12
GB2246783B true GB2246783B (en) 1992-10-14

Family

ID=10656000

Family Applications (2)

Application Number Title Priority Date Filing Date
GB898909916A Pending GB8909916D0 (en) 1989-04-29 1989-04-29 Polypeptides
GB9119043A Expired - Lifetime GB2246783B (en) 1989-04-29 1991-09-06 Fusion proteins containing n-terminal fragments of human serum albumin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB898909916A Pending GB8909916D0 (en) 1989-04-29 1989-04-29 Polypeptides

Country Status (12)

Country Link
EP (1) EP0470165A1 (en)
JP (1) JP2781459B2 (en)
KR (1) KR100227167B1 (en)
AU (1) AU630450B2 (en)
CA (1) CA2015687C (en)
FI (1) FI104255B1 (en)
GB (2) GB8909916D0 (en)
HU (1) HUT61049A (en)
IE (1) IE67651B1 (en)
IL (1) IL94243A (en)
WO (1) WO1990013653A1 (en)
ZA (1) ZA903237B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
FR2686900B1 (en) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
WO1994016085A2 (en) * 1992-12-30 1994-07-21 Zymogenetics, Inc. Hybrid proteins having cross-linking and tissue-binding activities
GB9408466D0 (en) * 1994-04-27 1994-06-22 Univ Nottingham Cloning and functional expression of neurotoxins
US5543308A (en) * 1994-10-18 1996-08-06 New England Biolabs, Inc. Isolated DNA encoding the FSEI restriction endonuclease and related methods for producing the same
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
US5877149A (en) 1995-06-07 1999-03-02 Beaulieu; Andre Deepithelialized skin diffusion cell system
AR008077A1 (en) * 1996-07-26 1999-12-09 Talarico Salinas Laura Beatriz A FUSION POLYPEPTIDE OR A SALT OF THE SAME, ITS USE, A PROCESS TO PREPARE THEM, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, AND A VECTOR.
US6423512B1 (en) 1996-07-26 2002-07-23 Novartis Ag Fusion polypeptides
US5932693A (en) * 1996-12-10 1999-08-03 Washington University Antithrombotic peptides
EP1049790A1 (en) 1998-01-23 2000-11-08 Novo Nordisk A/S Process for making desired polypeptides in yeast
US6548653B1 (en) 1998-06-15 2003-04-15 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
CA2405912A1 (en) * 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
TW200718784A (en) 2001-08-15 2007-05-16 Takara Bio Inc Method of extended culture for antigen-specific cytotoxic T lumphocytes
ES2545090T3 (en) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Albumin and GCSF fusion proteins
CA2479288C (en) 2002-03-25 2015-02-24 Takara Bio Inc. Process for producing cytotoxic lymphocyte
AU2004267313B2 (en) 2003-08-22 2009-09-24 Takara Bio Inc. Process for producing cytotoxic lymphocytes
EP2520654B8 (en) 2003-08-26 2017-04-19 The Regents of the University of Colorado, a body corporate Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
US9057061B2 (en) 2003-12-23 2015-06-16 Novozymes Biopharma Dk A/S Gene expression technique
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007146038A2 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
CA2657277C (en) 2006-07-13 2015-11-24 Upperton Limited Process for preparing particles of proteinaceous material
JP5936112B2 (en) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ Albumin variants and complexes
GB2488077A (en) 2009-10-30 2012-08-15 Novozymes Biopharma Dk As Albumin variants
CN106977608A (en) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 Albumin derivant and variant
EP2723370A4 (en) * 2011-06-24 2015-06-03 Univ Colorado Regents Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
CN104736559B (en) 2012-03-16 2022-04-08 阿尔布梅迪克斯医疗有限公司 Albumin variants
EP2917233A1 (en) 2012-11-08 2015-09-16 Novozymes Biopharma DK A/S Albumin variants
EP2968587A2 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
EP3337816B1 (en) 2015-08-20 2024-02-14 Albumedix Ltd Albumin variants and conjugates
WO2018089702A1 (en) * 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Gdnf fusion polypeptides and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002467A1 (en) * 1987-09-14 1989-03-23 Skandigen Ab Artificial gene coding for authentic human serum albumin, use thereof, and method of producing the same
EP0322094A1 (en) * 1987-10-30 1989-06-28 Delta Biotechnology Limited N-terminal fragments of human serum albumin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002467A1 (en) * 1987-09-14 1989-03-23 Skandigen Ab Artificial gene coding for authentic human serum albumin, use thereof, and method of producing the same
EP0322094A1 (en) * 1987-10-30 1989-06-28 Delta Biotechnology Limited N-terminal fragments of human serum albumin

Also Published As

Publication number Publication date
FI104255B (en) 1999-12-15
AU630450B2 (en) 1992-10-29
CA2015687C (en) 2000-08-29
WO1990013653A1 (en) 1990-11-15
FI915073A0 (en) 1991-10-28
IL94243A (en) 1995-10-31
KR920701451A (en) 1992-08-11
IE67651B1 (en) 1996-04-17
HU904413D0 (en) 1992-01-28
JP2781459B2 (en) 1998-07-30
KR100227167B1 (en) 1999-10-15
IE901554L (en) 1990-10-29
GB8909916D0 (en) 1989-06-14
FI104255B1 (en) 1999-12-15
GB2246783A (en) 1992-02-12
AU5564690A (en) 1990-11-29
JPH04506598A (en) 1992-11-19
IL94243A0 (en) 1991-01-31
HUT61049A (en) 1992-11-30
EP0470165A1 (en) 1992-02-12
CA2015687A1 (en) 1990-10-29
ZA903237B (en) 1991-03-27
GB9119043D0 (en) 1991-12-04

Similar Documents

Publication Publication Date Title
GB2246783B (en) Fusion proteins containing n-terminal fragments of human serum albumin
EP0324647A3 (en) Vector for the expression of fusion proteins and protein immunogens
GB8610551D0 (en) Polypeptide & protein derivatives
NZ235315A (en) Chimaeric hepadnavirus core antigen proteins and their construction
EP0491844A4 (en) Peptides including ctl epitopes of hiv proteins and use thereof
AU6428890A (en) Therapeutic peptides and proteins
IL79290A0 (en) Preparation of proteins and polypeptides
EP0209543A4 (en) Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use.
AU7034691A (en) Lipoprotein signal peptide fused to antigenic polypeptides
EP0227110A3 (en) Human immunoglobulin g fc region protein and production thereof
AU4927390A (en) Fusion proteins
IL95697A0 (en) Cdna sequence for porcine lactoferrin protein
IL86153A0 (en) Recombinant htlv-iii proteins and uses thereof
YU219289A (en) Recombinant hybride proteins of interleucine-2
AU1216988A (en) Immunogenic fusion proteins which contain Epstein-Barr virus protein
IL91462A0 (en) Recombinant fusion proteins and dna encoding for such a protein
IL94526A0 (en) Method for c-terminal modification of proteins
AU1996388A (en) Proteins and protein compositions and their use
IL96688A0 (en) Expression of delta-endotoxin proteins
IL89877A0 (en) Process for the preparation of proteins which start with n-terminal proline
ZA901695B (en) Recombinant protein receptor
ZA907279B (en) Antibodies and proteins
GB2205568B (en) Recombinant plasmids and silk-like proteins produced therefrom
PT86162A (en) Recombinant protein expression
IE892830L (en) Fusion protein of paramyxovirus

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Expiry date: 20100425